Chugai Pharmaceutical: To Recall Leukemia Drug In Japan (Japan)
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceutical Co. has started recalling a leukemia drug, Vesanoid, in Japan as a specified batch of the drug from its parent Roche Holding AG contained material that wasn't approved by the Japanese government. The company said capsules of the drug in this particular batch contained bovine-derived material sourced from Canada. Use of the material in question is approved overseas, but it requires special approval from the government in Japan. Roche had thought that the use of the material had been approved by the Japanese government and exported the batch to Japan. Chugai is recalling 1,998 bottles of Vesanoid Capsule shipped to 740 medical institutions between Jan. 5 and June 18 this year. (Click here for more - May Require Paid Subscription
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.